Status:
UNKNOWN
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Anticoagulation in COVID-19 ARDS
Eligibility:
All Genders
18-99 years
Phase:
PHASE4
Brief Summary
Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part of the disease is an activation of the coagulation system which seems to contribute to clotformation in th...
Detailed Description
The pandemic of COVID-19, a newly upcoming viral disease caused by SARS-CoV-2, puts the whole worlds health system under pressure. Patients suffering from this disease mainly develop respiratory symp...
Eligibility Criteria
Inclusion
- Adult patient (≥ 18 years of age)
- Positive COVID-test
- Under mechanical ventilation
- D-Dimers\>1.2 mg/L
Exclusion
- Pregnancy
- Allergy to the drug (bivalirudin)
- Inherited coagulation abnormalities
- No informed consent
Key Trial Info
Start Date :
June 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 28 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04445935
Start Date
June 28 2020
End Date
March 28 2021
Last Update
June 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, Qatar